NASDAQ:CRNX

Crinetics Pharmaceuticals (CRNX) Stock Forecast, Price & News

$21.67

-0.29 (-1.32%)

(As of 06/9/2023 ET)

Compare

Today's Range: $21.60
▼
$22.45
50-Day Range: $15.73
▼
$23.60
52-Week Range: $15.23
▼
$24.58

Volume: 534,752 shs
Average Volume: 470,374 shs
Market Capitalization: $1.17 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $45.50

Crinetics Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 110.0% Upside
$45.50 Price Target
Short Interest: Healthy
6.37% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.62
Upright™ Environmental Score
News Sentiment: 1.08
Based on 9 Articles This Week
Insider Trading: Selling Shares
$132,624 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.41) to ($3.46) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

215th out of 988 stocks

Pharmaceutical Preparations Industry

95th out of 482 stocks

3.5

Analyst's Opinion

Consensus Rating
Crinetics Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $45.50, Crinetics Pharmaceuticals has a forecasted upside of 110.0% from its current price of $21.67.
Amount of Analyst Coverage
Crinetics Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
6.37% of the outstanding shares of Crinetics Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Crinetics Pharmaceuticals has a short interest ratio ("days to cover") of 7.7.
Change versus previous month
Short interest in Crinetics Pharmaceuticals has recently decreased by 18.87%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Crinetics Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Crinetics Pharmaceuticals does not have a long track record of dividend growth.

3.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Crinetics Pharmaceuticals has received a 46.37% net impact score from Upright. Crinetics Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health", "Basic medical research services", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Crinetics Pharmaceuticals is -0.62.

2.8

News and Social Media Coverage

News Sentiment
Crinetics Pharmaceuticals has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Crinetics Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for CRNX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Crinetics Pharmaceuticals insiders have sold 20.24% more of their company's stock than they have bought. Specifically, they have bought $110,300.00 in company stock and sold $132,624.00 in company stock.
Percentage Held by Insiders
Only 5.90% of the stock of Crinetics Pharmaceuticals is held by insiders.
Percentage Held by Institutions
95.64% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Crinetics Pharmaceuticals are expected to decrease in the coming year, from ($3.41) to ($3.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Crinetics Pharmaceuticals is -6.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Crinetics Pharmaceuticals is -6.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Crinetics Pharmaceuticals has a P/B Ratio of 3.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Receive CRNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRNX Stock News Headlines

June 10, 2023 | americanbankingnews.com

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Director Coelho Rogerio Vivaldi Acquires 5,000 Shares

June 9, 2023 | finance.yahoo.com

Crinetics to Highlight Broad Pipeline at ENDO 2023

June 10, 2023 | Vantage Point (Ad)

Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.

There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.

June 8, 2023 | markets.businessinsider.com

Where Crinetics Pharmaceuticals Stands With Analysts

June 5, 2023 | markets.businessinsider.com

Crinetics Pharmaceuticals (CRNX) Receives a Buy from Piper Sandler

May 25, 2023 | seekingalpha.com

Crinetics Pharmaceuticals And Its Value Proposition In Acromegaly

May 22, 2023 | americanbankingnews.com

Brokerages Set Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Target Price at $44.20

May 17, 2023 | americanbankingnews.com

Crinetics Pharmaceuticals, Inc. Forecasted to Post FY2023 Earnings of ($3.62) Per Share (NASDAQ:CRNX)

June 10, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

May 15, 2023 | markets.businessinsider.com

Crinetics Pharmaceuticals (CRNX) Gets a Buy from Piper Sandler

May 9, 2023 | americanbankingnews.com

Crinetics Pharmaceuticals (NASDAQ:CRNX) Given New $43.00 Price Target at JMP Securities

May 9, 2023 | americanbankingnews.com

FY2027 Earnings Estimate for Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Issued By HC Wainwright

May 7, 2023 | americanbankingnews.com

Crinetics Pharmaceuticals (NASDAQ:CRNX) Reaches New 1-Year High Following Analyst Upgrade

May 6, 2023 | finance.yahoo.com

Crinetics Pharmaceuticals First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags

May 5, 2023 | msn.com

JMP Securities Maintains Crinetics Pharmaceuticals (CRNX) Outperform Recommendation

May 5, 2023 | msn.com

HC Wainwright & Co. Reiterates Crinetics Pharmaceuticals (CRNX) Buy Recommendation

May 5, 2023 | finanznachrichten.de

Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 5, 2023 | markets.businessinsider.com

Crinetics Pharmaceuticals (CRNX) Receives a Buy from H.C. Wainwright

May 5, 2023 | finance.yahoo.com

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates

May 4, 2023 | finance.yahoo.com

Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

April 24, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Crinetics Pharmaceuticals

April 24, 2023 | cnbc.com

Piper Sandler says buy this under-the-radar pharmaceutical stock poised to more than triple from here

April 24, 2023 | msn.com

Piper Sandler Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Overweight Recommendation

April 24, 2023 | americanbankingnews.com

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Rating of "Buy" by Analysts

April 24, 2023 | americanbankingnews.com

Piper Sandler Begins Coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX)

April 16, 2023 | finance.yahoo.com

The past year for Crinetics Pharmaceuticals (NASDAQ:CRNX) investors has not been profitable

April 7, 2023 | americanbankingnews.com

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Dana Pizzuti Sells 8,212 Shares

See More Headlines

CRNX Price History

30 days | 90 days | 365 days | Advanced Chart

CRNX Company Calendar

Last Earnings: 11/05/2021
Today: 6/10/2023
Next Earnings (Estimated): 8/11/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CRNX
CUSIP: N/A
CIK: 1658247
Web: www.crinetics.com
Phone: (858) 450-6464
Fax: N/A
Employees: 143
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $45.50
High Stock Price Forecast: $56.00
Low Stock Price Forecast: $35.00
Forecasted Upside/Downside: +110.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.28)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-163,920,000.00
Net Margins: -4,090.69%
Pretax Margin: -4,090.69%
Return on Equity: -52.55%
Return on Assets: -47.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.60
Quick Ratio: 11.60

Sales & Book Value

Annual Sales: $4.74 million
Price / Sales: 247.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.88 per share
Price / Book: 3.69

Miscellaneous

Outstanding Shares: 54,030,000
Free Float: 50,838,000
Market Cap: $1.17 billion
Optionable: Not Optionable
Beta: 0.94

Key Executives

Scott R. Struthers
President, Chief Executive Officer & Director

Jeff E Knight
Chief Operating Officer

Marc J. S. Wilson
Chief Financial Officer

Stephen F. Betz
Chief Scientific Officer

Alan Seth Krasner
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CRNX Stock - Frequently Asked Questions

Should I buy or sell Crinetics Pharmaceuticals stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRNX shares.
View CRNX analyst ratings or view top-rated stocks.
What is Crinetics Pharmaceuticals' stock price forecast for 2023?: 5 brokerages have issued 12 month price targets for Crinetics Pharmaceuticals' stock. Their CRNX share price forecasts range from $35.00 to $56.00. On average, they expect the company's stock price to reach $45.50 in the next year. This suggests a possible upside of 110.0% from the stock's current price.
View analysts price targets for CRNX or view top-rated stocks among Wall Street analysts.
How have CRNX shares performed in 2023?: Crinetics Pharmaceuticals' stock was trading at $18.30 at the beginning of the year. Since then, CRNX stock has increased by 18.4% and is now trading at $21.67.
View the best growth stocks for 2023 here.
When is Crinetics Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our CRNX earnings forecast.
How were Crinetics Pharmaceuticals' earnings last quarter?: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) announced its earnings results on Friday, November, 5th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.01. Crinetics Pharmaceuticals had a negative trailing twelve-month return on equity of 52.55% and a negative net margin of 4,090.69%.
What ETFs hold Crinetics Pharmaceuticals' stock?: ETFs with the largest weight of Crinetics Pharmaceuticals (NASDAQ:CRNX) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), iShares Micro-Cap ETF (IWC) and iShares Biotechnology ETF (IBB).
What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?: 6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend.
What other stocks do shareholders of Crinetics Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

When did Crinetics Pharmaceuticals IPO?: (CRNX) raised $80 million in an initial public offering on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.
What is Crinetics Pharmaceuticals' stock symbol?: Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."
Who are Crinetics Pharmaceuticals' major shareholders?: Crinetics Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.33%), Wellington Management Group LLP (6.73%), Perceptive Advisors LLC (6.58%), State Street Corp (4.11%), Braidwell LP (3.74%) and First Light Asset Management LLC (3.00%). Insiders that own company stock include Ajay Madan, Coelho Rogerio Vivaldi, Dana Pizzuti, Jeff E Knight, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers and Stephen F Betz.
View institutional ownership trends.
How do I buy shares of Crinetics Pharmaceuticals?: Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Crinetics Pharmaceuticals' stock price today?: One share of CRNX stock can currently be purchased for approximately $21.67.
How much money does Crinetics Pharmaceuticals make?: Crinetics Pharmaceuticals (NASDAQ:CRNX) has a market capitalization of $1.17 billion and generates $4.74 million in revenue each year. The company earns $-163,920,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis.
How many employees does Crinetics Pharmaceuticals have?: The company employs 143 workers across the globe.
How can I contact Crinetics Pharmaceuticals?: Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The official website for the company is www.crinetics.com. The company can be reached via phone at (858) 450-6464 or via email at ir@crinetics.com.

This page (NASDAQ:CRNX) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial